JP2018535684A5

JP2018535684A5 -

Info

Publication number: JP2018535684A5
Application number: JP2018528746A
Authority: JP
Filing date: 2016-08-31
Publication date: 2019-10-10

Claims

Use of at least one microRNA or a precursor thereof (pre-miRNA) for inducing proliferation or regeneration of CD34 positive adult stem cells in a cell matrix,
The cellular matrix may look contains at least one CD34-positive adult stem cells,
Wherein the at least one microRNA or pre-miRNA is seen containing a common seed sequence SEQ.ID.NO.3,
Growth or reproduction of the previous SL CD34-positive adult stem cells is induced by the at least one microRNA or pre-miRNA contacting said cell matrix, used.

The use according to claim 1, wherein the at least one microRNA or pre-miRNA is generated by driving RNA transcription by a eukaryotic promoter in prokaryotic cells.

Driving RNA transcription by the eukaryotic promoter may include chemical agents including 3-morpholinopropane-1-sulfonic acid (MOPS) and SEQ.ID.NO.6, SEQ.ID.NO.7, SEQ. 3.Induced by contacting with at least one transformed prokaryotic cell carrying at least one expression vector encoding the sequence of ID.NO.8 or SEQ.ID.NO.9. Use .

The use according to claim 3, wherein the expression vector is a recombinant plasmid encoding the sequence of SEQ.ID.NO.5.

4. The use according to claim 3, wherein the expression vector is pLenti-EF1alpha-RGFP-miR302 containing a cytomegalovirus (CMV) or mammalian EF1α (EF1alpha) promoter, or both simultaneously.

Use according to claim 2, wherein the prokaryotic cell is an E. coli competent cell.

The at least one microRNA or pre-miRNA is at least one hairpin sequence of SEQ.ID.NO.6, SEQ.ID.NO.7, SEQ.ID.NO.8, or SEQ.ID.NO.9. The use according to claim 1 comprising:

Wherein the at least one microRNA or pre-miRNA is miR-302 precursor produced by prokaryotes (pro-miR-302), Use according to claim 1.

9. Use according to claim 8, wherein the pro-miR-302 comprises at least one sequence of miR-302a, miR-302b, miR-302c, or miR-302d.

9. Use according to claim 8, wherein the pro-miR-302 is used as part of a drug component for pharmaceutical and therapeutic applications.

Wherein the at least one microRNA or pre-miRNA is used as part of a drug component of the pharmaceutical and therapeutic applications, use of claim 1.

Wherein the at least one microRNA or pre-miRNA or induced the CD34-positive adult stem cells, are used for the treatment of human aging-related diseases Use according to claim 1.

Induced the CD34-positive adult stem cells are used in a part of the processing of a pharmaceutical or therapeutic applications, use of claim 1.

The induced CD34 positive adult stem cells reprogram the malignant properties of human cancer cells in the body to a low grade benign state or a state similar to normal , or promote healing of scars without scars in the body , use according to claim 1.

The use according to claim 1, wherein the type of CD34 positive adult stem cell comprises skin, hair, muscle, blood (hematopoietic cell), stromal cell, and neural stem cell, or a combination thereof.

  Use of at least one microRNA or a precursor thereof (pre-miRNA) to treat a degenerative disease in a subject by re-growing and / or regenerating CD34 positive adult stem cells,
  The subject has at least one CD34 positive adult stem cell;
  The at least one microRNA or pre-miRNA comprises a common seed sequence SEQ.ID.NO.3,
  Use, wherein the at least one microRNA or pre-miRNA is provided to the subject to induce proliferation or regeneration of the CD34-positive adult stem cells.